Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Non-Current Debt (2019 - 2025)

Biodesix (BDSX) has disclosed Non-Current Debt for 7 consecutive years, with $47.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 30.31% year-over-year to $47.4 million, compared with a TTM value of $47.4 million through Dec 2025, up 30.31%, and an annual FY2025 reading of $47.4 million, up 30.31% over the prior year.
  • Non-Current Debt was $47.4 million for Q4 2025 at Biodesix, up from $47.1 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $47.4 million in Q4 2025 and bottomed at $4.9 million in Q3 2022.
  • Average Non-Current Debt over 5 years is $29.0 million, with a median of $30.2 million recorded in 2021.
  • The sharpest move saw Non-Current Debt tumbled 83.72% in 2022, then surged 411.27% in 2023.
  • Year by year, Non-Current Debt stood at $10.0 million in 2021, then soared by 150.22% to $25.0 million in 2022, then soared by 40.88% to $35.2 million in 2023, then grew by 3.36% to $36.4 million in 2024, then surged by 30.31% to $47.4 million in 2025.
  • Business Quant data shows Non-Current Debt for BDSX at $47.4 million in Q4 2025, $47.1 million in Q3 2025, and $46.8 million in Q2 2025.